Literature DB >> 15197197

Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.

Hojoong Kim1, Young Mi Kwon, Jin Seuk Kim, Haengbyoung Lee, Jung-Ho Park, Young Mog Shim, Joungho Han, Joobae Park, Duk-Hwan Kim.   

Abstract

PURPOSE: The aim of this study was to identify tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer (NSCLC) by differentiating the age-related methylation from the tumor-specific methylation in NSCLC. PATIENTS AND METHODS: Eighty-five NSCLC patients and 127 cancer-free subjects participated in this study. Aberrant methylation at the promoters of the p16, Ras association domain family 1A (RASSF1A), fragile histidine triad (FHIT), H-cadherin, and retinoic acid receptor beta (RARbeta) genes were evaluated in the resected tumor tissues and bronchial lavage samples of NSCLC patients and in the bronchial lavage samples of cancer-free subjects by methylation-specific polymerase chain reaction.
RESULTS: Of the 127 cancer-free samples, methylation was detected in 6% for p16, 13% for RARbeta, 3% for H-cadherin, 4% for RASSF1A, and 28% for FHIT. Hypermethylation of the p16, RARbeta, H-cadherin, and RASSF1A genes was not associated with patient age and smoking, whereas hypermethylation of the FHIT promoter occurred more frequently in older patients (P =.02) and was associated with exposure to tobacco smoke (P =.001). A strong correlation between age and smoking was found in patients with hypermethylation of the FHIT gene (r = 0.36; P =.03). A total of 68% of the bronchial lavage samples from the 85 NSCLC patients showed methylation of at least one of p16, RARbeta, H-cadherin, and RASSF1A genes.
CONCLUSION: Our study suggests that tumor-specific methylation of the p16, RASSF1A, H-cadherin, and RARbeta genes may be a valuable biomarker for the early detection of NSCLC in bronchial lavage, and that the age-related methylation of FHIT gene in the normal bronchial epithelium is related to the exposure to tobacco smoke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197197     DOI: 10.1200/JCO.2004.10.077

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

2.  Isolation and bioinformatics analysis of differentially methylated genomic fragments in human gastric cancer.

Authors:  Ai-Jun Liao; Qi Su; Xun Wang; Bin Zeng; Wei Shi
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 3.  Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings.

Authors:  Romulo Martin Brena; Tim Hui-Ming Huang; Christoph Plass
Journal:  J Mol Med (Berl)       Date:  2006-01-17       Impact factor: 4.599

Review 4.  Maternal smoking as a model for environmental epigenetic changes affecting birthweight and fetal programming.

Authors:  Melissa A Suter; Amber M Anders; Kjersti M Aagaard
Journal:  Mol Hum Reprod       Date:  2012-11-08       Impact factor: 4.025

5.  Molecular characterization of head and neck cancer: how close to personalized targeted therapy?

Authors:  Maria J Worsham; Haythem Ali; Jadranka Dragovic; Vanessa P Schweitzer
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

Review 6.  Delineating an epigenetic continuum in head and neck cancer.

Authors:  Maria J Worsham; Josena K Stephen; Kang Mei Chen; Shaleta Havard; Veena Shah; Glendon Gardner; Vanessa G Schweitzer
Journal:  Cancer Lett       Date:  2012-03-01       Impact factor: 8.679

Review 7.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

8.  Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.

Authors:  Linbo Gao; David Cheng; Jie Yang; Renyi Wu; Wenji Li; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2018-02-09       Impact factor: 6.048

9.  Quantitative detection of TUSC3 promoter methylation -a potential biomarker for prognosis in lung cancer.

Authors:  Uta Duppel; Matthias Woenckhaus; Christian Schulz; Johannes Merk; Wolfgang Dietmaier
Journal:  Oncol Lett       Date:  2016-08-01       Impact factor: 2.967

10.  Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India.

Authors:  Mohammad Raish; Varinderpal S Dhillon; Arif Ahmad; Mushtaq Ahmad Ansari; Shahid Mudassar; Mohammad Shahid; Vineeta Batra; Pawan Gupta; Bhudev Chandra Das; Nk Shukla; Syed Akhtar Husain
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.